Form D · Pharmaceuticals

Aptevo Therapeutics Inc.

Seattle, WA · CIK 0001671584

Offering snapshot reported Aug 26, 2026 · SEC filing

Reported sold
$3.47M
Offering amount: $3.47M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 12, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 26, 2026Initial$3,472,683No comparison3SEC filing
Apr 18, 2025Initial$2,100,004No comparison11SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$315K
Finders' fees
$0
Form D file number
021-595477
We paid an additional $90,000 in placement agent expenses.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Roth Capital Partners, LLC15407

Source: Form D, filed Aug 26, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Daniel J Abdun Nabi Director
Grady Grant Iii Director
Zsolt Harsanyi Director
Jeffrey G Lamothe Director, Executive
Barbara Lopez Kunz Director
John E Niederhuber Director
Daphne Taylor Executive
Marvin L White Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2401 4th Ave. Suite 1050
Seattle, WA, 98121
Phone: 206-838-0500